Despite the
Embryonic stem cells (ESC's) having the potential to provide unlimited cells
and tissues for regenerative medicine, their use is difficult
because most of them will be rejected by the patient’s immune system unless
officially immunomastched.
Although
pluripotent stem cells are genetically identical to a patient, they can be
established by reprogramming of somatic cells. Limitations remain high cost and
they are required to produce clinical grade cells for each kind of patient.
The ESC's derived
from parthenogenetic embryos (pESC) which are homozygous for HLA 'S may serve
as an alternative for immunomatched therapies for a large number of patients.
No comments:
Post a Comment